Tikun Olam - Cannbit Pharmaceuticals Ltd.

cannbit.com

Formerly Cannbit Pharmaceuticals

High-Tech Company
Public Company

(TASE: TKUN)

TECH VERTICALS

Biologicals, Biotechnology, Life Sciences, Medical Cannabis, MedTech

General Data

Sector	Biomed
Company Stage:	Initial Revenues
Established	2005
Number of Employees	40
Reg. Number:	abCDe

DESCRIPTION

Cannbit is involved with the growth of medical cannabis, and intends to operate in the field of production, including the establishment of a plant and marketing of cannabis products for medical use.
Cannbit are building the best Cannabis company this side of the pond by creating a unique and visionary Cannabis Ecosystem.

A team of researchers from the Hebrew University have done research on molecules that have been found to be effective in cancer treatment. That is, in practice, this is not a drug produced from the cannabis plant, but a chemical molecule that simulates cannabinoid activity. This gave researchers initial indications in the lab that it may be effective in treating melanoma (skin cancer), and neuroblastoma and glioblastoma (types of brain cancer) - and lead to withdrawal.

TECHNOLOGY

Cannabinoids

	TARGET MARKETS
	Cannabis research in the field of cancer

	BUSINESS MODEL
	B2B

CONTACT INFO

Expand / Collapse All

Main Address: Tel Aviv, Israel

Address	9 Hashla st.
City	Tel Aviv
Country	Israel
Zip	6473921

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Liad Anani	CFO
Mr. Yaron Razon	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	N\A

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

Nov. 18, 2018

R&D

abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Jan. 01, 2020	Third Public Offering	TASE	abCDe	abCDe	Raised NIS 26.5m; Valuation NIS 245m.
Apr. 18, 2019	Second Public Offering	TASE	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Sep. 09, 2021

R&D

abCDe

PIPE

Jul. 20, 2021

R&D

abCDe

NIS 6m

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Hedge Fund	abCDe	Holds 5.9% of the company
abC Defghij	Private Investor	abCDe

PIPE

Feb. 07, 2021

R&D

abCDe

PIPE

Jun. 10, 2020

R&D

abCDe

NIS 11.5

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Insurance	abCDe
abC Defghij	Other	abCDe

PIPE

Jan. 06, 2020

R&D

abCDe

PIPE

Dec. 22, 2019

R&D

abCDe

NIS 26.5m

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe	NIS 1.5m
abC Defghij	Private Investor	abCDe	NIS 1.5m
abC Defghij	Private Investor	abCDe	NIS 3.2m
abC Defghij	Private Investor	abCDe	NIS 3.6m
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe	NIS 3.4m

PIPE

Dec. 11, 2019

R&D

abCDe

PIPE

Jun. 06, 2019

R&D

abCDe

PIPE

Apr. 15, 2019

R&D

abCDe

Raised NIS 32m.

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

	Acquisitions made by Tikun Olam Cannbit

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	N/A	Nov. 25, 2019	abCDe	$23m in cash plus 5% of Cannbit shares.

	PORTFOLIO COMPANIES

Current Portfolio Companies (1)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Gynica

Biomed

First Round

24/06/2021

$1.5m

Last Updated:	abCDe
IVC Number:	abCDe